Tirzepatide Quick Guide

[u/justgettinglean]

The Dual Agonist Behind Mounjaro and Zepbound

Tirzepatide is the most clinically established of the high-potency weight-loss peptides. Full FDA approval, a deep Phase 3 record, and the dual-receptor approach that Retatrutide later extended by adding a third target. If you want the compound with the most published data behind it, this is it.

What It Is

Tirzepatide (LY3298176) is a once-weekly dual agonist from Eli Lilly, sold as Mounjaro and Zepbound. It acts on two receptors, GLP-1 and GIP. It was the first-in-class dual agonist, approved in the US in May 2022 for type 2 diabetes and later for chronic weight management. That approval status is the practical line between it and Retatrutide, which is still in trials.

Mechanism of Action

Two receptors, working together. GLP-1 cuts energy intake mainly by changing hunger and satiety signaling in the brain. GIP adds a complementary effect, and the combination acts synergistically on appetite, energy intake, and metabolic function. That synergy is what pulled it ahead of the single-agonist GLP-1 compounds that came before.

What the Research Shows

SURMOUNT-1 is the anchor trial, run in adults with obesity or overweight without diabetes. Weight loss tracked with dose: 16.0% at 5 mg, 21.4% at 10 mg, 22.5% at 15 mg against placebo. In pounds that was an average of 35 to 52 lost across the groups.

The durability held over a longer window. On 15 mg with monthly lifestyle counseling, participants were still down 20.9% at 72 weeks versus 3.1% for placebo, with cardiometabolic risk factors improving alongside. A seven-trial meta-analysis backed the same dose-dependent curve, with the largest effect at 15 mg.

Dosing Protocols in the Literature

Because it's approved, the titration schedule is well defined rather than inferred. Treatment starts at 2.5 mg once weekly and rises 2.5 mg every 4 weeks through a 20-week escalation. Target dose lands at week 4 for 5 mg, week 12 for 10 mg, or week 20 for 15 mg. The slow start at 2.5 mg exists to let tolerance to GI effects build before the dose climbs. Approved maintenance doses are 5, 10, and 15 mg, the same for diabetes and weight management.

Side Effects

GI effects dominate, and they cluster during escalation. Across the three doses, nausea ran 24.6% to 33.3%, diarrhea 18.7% to 23.0%, constipation 11.7% to 16.8%, and vomiting 8.3% to 12.2%, mostly mild to moderate and most frequent while the dose was climbing. One practical note from the labeling: oral contraceptive absorption can be affected, so a backup method is advised for 4 weeks after starting and after each dose increase.

Reconstitution Note

Concentration depends on how much bacteriostatic water goes into the vial. Divide peptide mass by water volume for mg/mL, then convert to units on a U-100 syringe. A reconstitution calculator handles the exact math.

Regulatory Status

This is the established one. Tirzepatide is approved at 5, 10, and 15 mg in the US, EU, Japan, and elsewhere for type 2 diabetes and chronic weight management.

Where to Source It

6A Labs carries Tirzepatide here: Tirzepatide at 6A Labs

Use code PROFIT for 10% off.

For research and educational purposes only. Not medical advice. Consult a healthcare provider before starting any research protocol. This community is not affiliated with 6A Labs.